Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline
Executive Summary
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
You may also be interested in...
Novo Nordisk’s Once-Weekly Insulin Gains Superiority Finding As Lilly Advances
The ONWARDS 1 and 6 results closely follow success in ONWARDS 2 in April, further helping strengthen insulin icodec’s potential market position, but Lilly is nipping at Novo’s heels.
Five (Non-COVID) Clinical Trial Hits Of 2021
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
Five (Non-COVID) Clinical Trial Hits Of 2021
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, Scrip takes a look at five of the more notable clinical trial hits of the year that got readers clicking.